AU Patent

AU2020231322A1 — Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus

Assigned to Lexicon Pharmaceuticals Inc · Expires 2021-09-02 · 5y expired

What this patent protects

The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m

USPTO Abstract

The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m

Drugs covered by this patent

Patent Metadata

Patent number
AU2020231322A1
Jurisdiction
AU
Classification
—
Expires
2021-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Lexicon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.